 WATERTOWN, Mass., April 09, 2021 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring new data in patients with hidradenitis suppurativa HS from its non-interventional study of patients with HS or atopic dermatitis AD has been selected for presentation at the Society for Investigative Dermatology SID 2021 Annual Meeting, being held virtually May 3-8, 2021. The non-interventional study is evaluating expression of IRAK4 and other mediators of inflammation in the skin and blood of patients with HS or AD and the ex vivo effect of the IRAK4 degrader KT-474. 